Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y Tanaka, N Nishida, M Sugiyama, M Kurosaki, K Matsuura, N Sakamoto (2009)
Genome wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis CNat Genet, 41
DL Thomas, J Astemborski, RM Rai, FA Anania, M Schaeffer, N Galai (2000)
The natural history of hepatitis C virus infection: host, viral, and environmental factorsJAMA, 284
M Derbala, NM Rizk, S Al-Kaabi, A John, M Sharma, N El-Dweik (2013)
The predictive value of IL-28B rs129860, rs11881222, and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patientsVirology, 444
MG Ghany, DR Nelson, DB Strader, DL Thomas, LB Seeff (2011)
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 54
TR Morgen, MG Ghany, HY Kim, KK Snow, ML Shiffmann, JL Santo (2010)
Outcome of sustained virological responders with histologically advanced chronic hepatitis CHepatology, 52
BJ Veldt, EJ Heathcote, H Wedemeyer, J Reichen, WP Hofmann, S Zeuzem (2007)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosisAnn Intern Med, 147
V Saludes, MA Bracho, O Valero, M Ardevol, R Planas, F Gonzalez-Candelas (2010)
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factorsPloS One, 5
L Prokunina-Olsson, B Muchmore, W Tang, RM Pfeiffer, H Park, H Dichensheets (2013)
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNat Genet, 45
K Hanafiah, J Groeger, AD Flaxman, ST Wiersman (2013)
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceHepatology, 57
MP Manns, JG McHutchison, SC Gorden, VK Rustigi, M Shiffman, R Reindollar (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trialLancet, 358
L Zhang, N Jilg, RX Shao, W Lin, DN Fusco, H Zhao (2011)
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathwayJ Hepatol, 55
P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Goncales (2005)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinJ Hepatol, 43
MG Ghany, DB Strader, DL Thomas, LB Seeff (2009)
Diagnosis, management, and treatment of hepatitis C: an updateHepatology, 49
S Bibert, T Roger, T Calandra, M Bochud, A Cerny, N Semmo (2013)
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance predictionJ Exp Med, 210
JE Everhart, EC Wright (2013)
Association of ?-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV)Hepatology, 57
MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Goncales (2002)
Peginterferon alfa-2a plus rivavirin for chronic hepatitis C virus infectionN Engl J Med, 347
I Lazarevic, J Djordjevic, M Cupic, D Karalic, D Delic, N Svirtlih (2013)
The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis CJ Clin Virol, 58
AG Singal, ML Volk, D Jensen, AM Bisceglie, PS Schoenfeld (2010)
A sustained viral response is associated with reduced liver related morbidity and mortality in patients with hepatitis C virusClin Gastroenterol Hepatol, 8
D Ge, J Felly, AJ Thomapson, JS Simon, KV Shianna, TJ Urban (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 461
V Weich, E Herrmann, TL Chung, C Sarrazin, H Hinrichsen, P Buggisch (2011)
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alphar based therapy in HCV type-1 infectionJ Gastroenterol, 46
H Toyada, T Kumada, N Shimada, K Takaguchi, T Ide, M Sata (2013)
Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter studyJ Med Virol, 85
CM Lange, S Zeuzem (2011)
IL28B single nucleotide polymorphisms in the treatment of hepatitis CHepatology, 55
V Saludes, E Bascunana, E Jordana-Lluch, S Casanovas, M Ardevol, E Soler (2013)
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b infected patientsPLoS One, 8
DM Jensen, TR Morgan, P Marcellin, PJ Pockros, KR Reddy, SJ Hadziyannis (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 KD)/ribavirin therapyHepatology, 43
X Guo, Z Zhao, J Xie, Q Cai, X Zhang, L Peng (2012)
Prediction of response to pegylated-interferon-? and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotypeVirol J, 9
S Bruno, A Crosignani, C Facciotto, S Rossi, L Roffi, A Redaelli (2010)
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up studyHepatology, 51
SJ Hadziyannis, H Sette, TR Morgen, V Balan, M Diago, P Marcellin (2004)
Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med, 140
TT Tran (2012)
A review of standard and newer treatment strategies in hepatitis CAm J Manag Care, 18
JW Yu, GQ Wang, LJ Sun, XG Li, SC Li (2007)
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirinJ Gastroenterol Hepatol, 22
J Garcia-Samaniego, M Romero, R Granados, R Aleman, MJ Juan, D Suarez (2013)
Factors associated with early virological response to peginterferon-alpha-2a/ribavirin in chronic hepatitis CWold J Gastroenterol, 19
Although the single-nucleotide polymorphism (SNP) rs12979860 in the IL28B gene is a better predictor of sustained virological response to treatment of chronic hepatitis C (CHC) than other baseline factors, some CHC patients with the favorable C allele cannot achieve a sustained virological response when treated with peginterferon plus ribavirin. The aim of this study was to examine baseline factors as predictors of rapid virological response (RVR) and complete early virological response (cEVR) to peginterferon alfa-2a plus ribavirin treatment in Chinese CHC patients with hepatitis C virus (HCV) genotype 1b, with emphasis on the difference between the rs129860 CC and CT/TT genotypes. A total of 337 treatment-naïve patients participated in this study. All patients were treated with peginterferon alfa-2a plus ribavirin at standard dosage. Serum samples from all patients were collected at baseline, week 4, and week 12 for testing of laboratory parameters, and IL28B genotypes were determined. Multivariate analysis showed that among rs12979860 CC genotype patients, glucose level and aspartate amino transferase (AST) activity were inversely associated with RVR, while abnormal platelet count and allergy inversely associated with cEVR. Among rs12979860 CT genotype patients, age below 40 years and short infection duration were associated with RVR, while age below 40 years, short infection duration, high body mass index (BMI), and no history of allergies were associated with cEVR. The baseline factors associated with the response to CHC treatment may depend on the IL28B genotype. Refinement of the baseline predictors based on IL28B genotypes may be useful for management of HCV infection.
Archives of Virology – Springer Journals
Published: Apr 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.